Article

Sensitization of resistant cells with a BET bromodomain inhibitor in a cell culture model of deep intrinsic resistance in breast cancer

2022-07-19

Abstract excerpt

<h4>Background: </h4> Cell culture models of cancer typically favor proliferative but therapy-sensitive cells because body-like selection pressures are absent. To address this limitation of cell culture, we previously described a function-based selection strategy to model deep intrinsic resistance in cultures of triple-negative breast cancer cells. To determine the validity of this approach in identifying noncytot...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8ee3189b-e342-5eff-aec2-92046e948df1
DOI: 10.21203/rs.3.rs-1832724/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sensitization of resistant cells with a BET bromodomain inhibitor in a cell culture model of deep intrinsic resistance in breast cancerDOI 10.21203/rs.3.rs-1832724/v1Read

A ‘one-two punch’ therapy strategy to target chemoresistance in estrogen receptor positive breast cancerSemantic proximity Read

Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cellsSemantic proximity Read

Heterogeneous therapy-resistant cancer cells have distinct and exploitable drug sensitivity profilesSemantic proximity Read

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancerSemantic proximity Read

Combating subclonal evolution of resistant cancer phenotypes.Semantic proximity Read

Mapping the Pathways of Resistance to Targeted TherapiesSemantic proximity Read

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.Semantic proximity Read

Drug resistance to targeted therapies: Déjà vu all over againSemantic proximity Read

Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic ResponseSemantic proximity Read

<i>In Silico</i> Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer TreatmentSemantic proximity Read

Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancerSemantic proximity Read

Treatment Resistance in Stem Cells and Breast CancerSemantic proximity Read